Biogen's Diranersen Demonstrates Efficacy Throughout All Doses In Phase 2 CELIA Trial Of Alzheimer’s Disease; Consistent Efficacy Seen Across Multiple Prespecified Secondary Endpoints Including Clinical Dementia Rating Sum Of Boxes

Loading news article.

Biogen's Diranersen Demonstrates Efficacy Throughout All Doses In Phase 2 CELIA Trial Of Alzheimer’s Disease; Consistent Efficacy Seen Across Multiple Prespecified Secondary Endpoints Including Clinical Dementia Rating Sum Of Boxes | WAPE

Biogen's Diranersen Demonstrates Efficacy Throughout All Doses In Phase 2 CELIA Trial Of Alzheimer’s Disease; Consistent Efficacy Seen Across Multiple Prespecified Secondary Endpoints Including Clinical Dementia Rating Sum Of Boxes

Article summary

Related companies

Comments —